Searched for
RESEARCH INDIANIVESH LTD.
Zero-budget farming may not be a good move for fertiliser companies: Experts"Negative for fertilizer companies as zero-budget farming significantly cuts down on agri-input consumption, Mr. Aksh Vashisth, analyst- ch...- Budget 2020: FDI to increase, Indian IT firms to benefit from FM's Data Centre planFM Sitharaman's proposal in the Union Budget to come up with a policy for setting up data centre parks would benefit tech services companie...
- Cotton prices to remain weak due to poor demand from ChinaThis year the government expects cotton production to be 32.26 million bales.
- As Samvat 2075 ends for market, Dalal Street rates its show poorlyEquity market performance on the larger or broader scale was disappointing in Samvat 2075.
- Gold Rate Today: Gold edges higher on weaker rupee, global worriesSilver prices jumped to Rs 47,747 per kg today.
- Affordable housing trends on D-Street tooCompanies like Gruh Finance and DHFL, which provide loans to affordable housing for the middle and low income segments, rose up to 8%.
- Buy Balrampur Chini, target Rs 140: Daljeet Singh Kohli"After the March quarter results, sugar sector has shown a very good set of numbers. In the space, we like
- See no arbitrage opportunity in IDFC; better wait for demerger: Daljeet Singh KohliIf you are buying IDFC due to the banking trigger, then let the NBFC commence banking operations first, says Kohli.
- Don't prefer SKS Microfinance on stretched valuations, looming regulatory concerns:'You should buy it only bargain'
- Investors are in the buying mode: Daljeet Singh Kohli, IndiaNivesh Ltd"They were all cautious. One would say that one will have to look at their numbers and a little bit of confidence was shaking."
- OMC stocks unattractive, wait for further corrections: Daljeet Singh Kohli'Therefore, valuations in all these companies have gone much beyond their fundamentals and therefore there was a need to react.'
- Prefer Torrent Pharma in midcap pharma space; see stock at Rs 1,677: Daljeet Singh KohliTorrent Pharma Q1 numbers were ahead of expectations, although some people have raised questions over what is next, says Kohli.
- We have a buy rating on Capital First with a target of Rs 460: Daljeet Singh Kohli, IndiaNiveshThey are not dependent on monsoons, they are not dependent on rural economy and therefore, may not have any adverse impact from deficient m...
- Risk-averse investors should prefer Sun Pharma over SPARC: Daljeet Singh Kohli, IndiaNivesh LtdIf they have to play this group, they should play through Sun Pharma, which has a sustainable business and there is visibility of earnings ...
- Bad debt worries spooking banking stocks; be selective: Daljeet Singh KohliKohi believes that NPAs will see a sharp rise in Q4FY15. He though believes that the problem will start fading away as soon as GDP growth r...
- Rail stocks plunge up to 13% on profit-bookingRail stocks today fell up to 13 per cent on heavy profit booking ahead of the Railway Budget for 2015-16 on Thursday.
- Buy Lumax Auto Technologies and Indoco Remedies: Daljeet S KohliThe rest are reiteration of the previous ones HSIL, we have increased the target price to Rs 485 now from earlier target of Rs 380.
- Recommend to avoid microfiance space: Daljeet Singh KohliI do not like this business model of going into microfinance because mainly my concern is that these deals with very poor people.
- Should Jindal Steel & Power be bought after 20% fall in two days?JSPL will have to pay retrospective penalty, cash flows will be hit due to purchase of expensive coal and uncertainty for re-allocation of ...
- Infosys shares pare losses; end nearly 2% upShares of IT major Infosys today reversed early losses and ended nearly 2 per cent higher, led by value buying at lower levels in a bullish...
Load More
